...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!
Due Dilligence
Annual General Meeting Presentation 6/22/2021
See also imtesty's rough transcript here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/762730-reposting-with-link-included/messages/2320824#message
Posted by:
BearDownAZ
on
Jun 23, 2021 09:13AM
May 12, 2021: PBA à Noon Presentation with Resverlogix Corp.
See also imtesty's rough transcript here: https://agoracom.com/ir/Resverlogix/forums/discussion/topics/760671-rough-transcript-rvx-21-05-12-pba-at-noon/messages/2315891#message
Posted by:
BearDownAZ
on
May 18, 2021 10:42AM
Resverlogix Corp. Links
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
Posted by:
BearDownAZ
on
Jan 12, 2021 08:05AM
AHA 2020: Reduction in the Risk of Major Adverse Cardiovascular Events with Apabetalone, a BET Protein Inhibitor, in Patients withRecent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the BETonMACE Trial
Posted by:
BearDownAZ
on
Nov 16, 2020 10:23AM
AHA 2020: BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes from Patients with Cardiovascular Disease and Type 2 Diabetes
Posted by:
BearDownAZ
on
Nov 14, 2020 05:28PM
AHA 2020: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry
Posted by:
BearDownAZ
on
Nov 14, 2020 05:27PM
Cardiovascular Therapeutics article: Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease
Posted by:
BearDownAZ
on
Nov 14, 2020 05:25PM
Medicinal Research Reviews article: Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases
Posted by:
BearDownAZ
on
Nov 14, 2020 05:24PM